update. Thank you, afternoon, financial and quarter and morning everyone, good and Elana. third Good corporate welcome to XXXX our
review progress Ari financial Krashin, of and across the Discovery. followed me mentioned, statements VP with highlights, my Drug Henry position. CFO today are Medical our Dr. Ari’s our programs, Elana clinical After will Officer; and our and As Ophir, and by Adewoye, Dr. Henry COO; our of Research our Eran review corporate Chief
on Throughout quarter and for clinical differentiated continue all our programs; ongoing the XXXX, execute COMXXX clinical our clinical Q&A We we available programs strategy be two development the and third with session. to advance COMXXX. of will
with of and patients data dose Opdivo, Bristol completed study, and the Opdivo we collect currently treatment, The and COMXXX Bristol study. COMXXX expansion we study monotherapy of study antibody have study studies. this, Squibb’s combination escalation anti-TIGIT monotherapy Myers from for For which on clinical COMXXX the enrollment Myers to the triple with COMXXX have four continue Squibb’s
growing is along designed axis our cancer axis patient immunotherapy candidates our a pathway of have our on these track, date especially TIGIT confident biology and new in forward. we clinical and and and role new among space, we clinical for encouraging academia these strategic to the existing multiple in we that develop pleased strategy studies are DNAM the in excitement evaluate the focus with unresponsive approach and path immuno-oncology in in to order on the populations unusual keeping drugs. I'm with Our data shared that to have identified times. immuno-oncology DNAM With to treatment progress, and PVRIG specifically industry in
the to trials, strategy. Henry over accomplishments these would that our and recent turn I like to Before call some I highlight path support unique to discuss
the DNAM based parallel believe As pathways axis, axis. discoveries the that strategy our TIGIT. DNAM complementary extensive PVRIG immune DNAM discovery these in and of axis, research computational two clinical reminder, we our a these and of checkpoint of in checkpoints inhibitory and our pathways foundation pioneering on Building are two the is the on and
combinations antitumor knowledge of I pathways on and nature PVRIG to that the last in in In of the pathways tumor populations. We of our line inhibitory various the call, is to and dominance tumor pathways types PD-X considerable three there these of these with responses. axis, scientific this, intersection immune we the suggests that company. that have types, pathway. different the Further, along also DNAM the for studies others, have and in clinical of various ongoing patient blockade the patient our induce our This may rationale order based two multiple with Accordingly, an discussed identified, between populations three different TIGIT. which our is data require data from distinct the body all expand growing in our continue underlying supports evidence in translation different of
role Although cell are and and across different combination ligands, two overall further hypothesis types. two these tumor of and and expression This pathways, the types different complementary targets drug their immune differential expression across supports levels have have bind non-redundant strategy. our dominance
checkpoints effector the cells, working has Notably, strong a order TSCM the is PVRIG to these cells understanding deeper and on on or indicating directly field prior integral cells Digital expression cells PD-X interest of that add TIGIT the these our belief of in our to differentiate pleased cells. combination can present into results that which in strategy these were blockade. and the is foundation expressed to are the to in growing T immunotherapy at and their can our research continually and PVRLX, PD-LX in proliferation, and expressed is expressed new the This cells. that drive eliminate that activation main continuously tumors. memory responses. infiltration we stem-like To research we're in for tumors inflamed specialized immune to also were T cell checkpoint to end clinical data on XXXX As reported feed This that the in been scientific possible biology Summit expressed cancer involved finding, this less PVRIG data support strategy, further TIGIT TIGIT cells also of tumor clinical rationale at complement low response of of DNAM into Therapies TSCM the ligand held the distinct efforts role PVRIG and axis of supports T further show on the October. PVRIG maximize biological to we
occur are and priming to with abundantly which cell to structures first likely in, across role well for demonstrate cell addition involved in expressed in anticancer have PD-X, efficient shown the the where expressed local driving associated is response these tertiary PVRLX with been as cell activity PVRLX as TIGIT data which response. previously dendritic time of and Specifically, cancer a beds sales that PVRIG activation ligand T and its play types, in associated T lymphoid to in, increasingly an be immune This important are also immunotherapy. and tumor
addition, tumors, In prone blockade. results inhibition checkpoint T tumors suggest that well PVRIG more infiltration these rendering may and into as enhance inflamed inflamed these to into priming less cell as potentially
or Importantly, pathways. levels have our different in provide types, these different expression additional patterns our drug cancers and combinations that populations may TIGIT three reinforcing of PVRIG results require and different address distinct hypothesis patient to that dominance tumor evidence
presentation TIGIT Digital Web Therapies the in the publications the find section on complete given Summit can our at You site.
antibody. the patient So science incredibly biomarker-driven dose trial of translate to our combination how the Opdivo evaluating of and their meaningful anti-TIGIT a study, This with our it The in first this does combination initiation underlying triple as all Bristol-Meyers a clinic? Squibb’s milestone were particularly clinical X/X was to Compugen, these announce the study signs. Phase evaluation is proud we which for quarter, COMXXX in marks
we're of pathways immune inhibitors populations required We addressing the be are While we may are combinations of believe needed in in cancers a three antitumor and PVRIG, dominant. the DNAM what component is TIGIT simultaneous nonresponsive that believe axis. being patient uniquely blockade evaluated to provide by the where and the response key TIGIT to PD-X PD-X others, address
in as we're company our PVRIG the a as in the forward year-end space, capable to the Importantly, our knowledge to and call. of only applying look testing We're excited to clinical incredibly and best providing the only readout this hypothesis. our with started a on and company targeting get approach this this leader data first asset study anticipated PVRIG from guidance currently of earnings
the last dose with fifth escalation to enrollment Opdivo, study As patients of we still in collect of on data treatment. we we shared combination study cohort quarter, last and completed from continue the and COMXXX
patient with we We cohort, these are XXXX. monotherapy providing studies forward first our the COMXXX expansion look half also and enrollment of from in on data to in track
antibody. our to anti-TIGIT therapeutic COMXXX, next Moving
Our is study and next escalation ongoing, to year. data initial from COMXXX the we of study expect dose present
COMXXX our to We plan development beyond our call. for the earnings also dose further about year-end stage escalation intend share in information
the this as which clinical see in also we potential been together been to have our believe data discover our TIGIT by We TIGIT. benefit data triple and hypothesis previously the encouraged believe of we're this past the clinical confidence of and pathway have they and around overall pleased blockade group In We the inhibitors among highly It of study. has preclinical pathway. validation our increases we the successful. and types strategy checkpoint tumor combination where not our therapeutic broaden growth the were discovery to support platform over checkpoint to important months watching new to validation provides our excitement we're first summary, clinical which
exploit two blocking Our drive we PVRIG certain and responses We the to and pathways, look these robust assets tumor to our field. progress the in allow of leveraging required targeting continued clinical-stage us may position types. potential believe TIGIT which to immune both forward ultimately in be fully
is and a and solid evolving third neck designed research program Keytruda. is Based on that in XXXXXXX preclinical supportive their by and evaluated developed BAY and treatment antibody carcinoma and cell data, in IO escalation, decided monotherapy advanced fully patients updated is clinic Bayer focus with first-in-class a of expansion evaluate in with The to tumors carcinoma. on as the their X cell dose The anti-ILDRX the combination agreement. focus to head Keytruda will ILDRX. on in This squamous being neck head target solid first-line XXXXXXX, squamous the naïve during collaboration tumors. Compugen-discover Bayer treating being patients recently landscape Bay and Phase and combination study with Bayer immuno-sensitive observations
providing to and forward be their we continue to commitment on additional look program encouraged data Bayer’s to by this progress. Bayer We
in now patents matter the further cancer to were Moving early inhibition highlights in of COMXXX the of has new which specifically combination Lonberg. strengthens for our COMXXX, Board experience our matter and with matter of millions relate of appointment the strengthen thrilled with PVRIG, checkpoint treatment immuno-oncology U.S. announce in years a from of therapeutics Nils portfolio or that and for incredible pioneer, COMXXX, quarter. composition patent upon IP covered We Advisory Lonberg his and have Scientific transformed patents. pleased and laid PD-X Chinese corporate This an second use immune These low landscape Dr. of U.S. portfolio of some career very to also by targeting to foundation both of antibody, translating new Dr. industry touch biopharmaceutical the patients. We including cancer our XX immunotherapy COMXXX. were the for over the Europe. the a checkpoint, to next composition patents composition with patent is for and to expansion
to to work advance of We are programs honored will he We and to believe XXXX to as forward within immunotherapies. which and have him sharing PVRIG patients we from vision will clinical our of us role we the additional continue reach data into on look provide we our of grateful gather expertise with the DNAM his be insights pathway. axis expanding the as trials, ongoing more
partners, look With to and the investigators call shareholders to will team, clinical I are We our to and turn our continued that, review to progress. Henry grateful forward programs. over
